methotrexate / Generic mfg. - LARVOL DELTA

Hesperidin methyl chalcone alleviates imiquimod-induced psoriasis in mice: effects alone and in combination with methotrexate. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "In conclusion, this study provides the first preclinical evidence that HMC, particularly in combination with MTX, ameliorates IMQ-induced psoriasis via modulation of inflammatory cytokines, oxidative stress, and histopathological damage. These findings suggest its potential as a therapeutic candidate that warrants further preclinical and clinical investigation in plaque-type psoriasis."

Journal • Preclinical • Dermatology • Immunology • Oncology • Psoriasis • IL17A • TNFA

The "Route Cause" of Methotrexate-Induced Brain Structure Changes in a Juvenile Mouse Model: Comparison of Systemic and CNS-Targeted Chemotherapy. (PubMed, Neurotoxicology) - "Comparison of systemic and intrathecal delivery routes revealed that systemic MTX had a wider impact on brain morphology than did IT MTX treatment, particularly at clinically relevant doses of IT MTX. This finding provides important insight into the mechanisms that likely underlie MTX-induced neurotoxicity and focuses potential interventions on systemic toxicity."

Journal • Preclinical • Acute Lymphocytic Leukemia • Cognitive Disorders • Hematological Malignancies • Leukemia • Oncology • Pediatrics • TP63

A phase 2 study of prophylactic intrathecal chemotherapy to prevent high-grade immune effector cell–associated neurotoxicity syndrome (ASH 2025) - "While prophylactic corticosteroids and cytokine-directed therapies like the IL-1 receptor antagonist anakinra have been explored, they carry potential risks and inconsistent efficacy...Study Design and This is a single-center, open-label, phase 2 trial evaluating the prophylactic use of IT methotrexate (12 mg), cytarabine (50 mg), and hydrocortisone (50 mg) in patients receiving standard-of-care axi-cel or brexu-cel for relapsed/refractory large cell or mantle cell lymphoma respectively...If effective, this approach could reduce the need for systemic corticosteroids, which are associated with significant morbidity. Further, prophylactic intrathecal therapy may be generalizable across existing and emerging CAR T-cell platforms, expanding eligibility to patients who might otherwise be excluded due to a high risk of neurologic toxicity."

P2 data • Acute Lymphocytic Leukemia • Brain Cancer • CNS Disorders • Epilepsy • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma

Characterization of pityriasis rubra pilaris with hematological malignancies: Paraneoplastic disease and targeted therapy reactions (ASH 2025) - "The ALL patient was related to ponatinib, the non-Hodgkin's lymphoma case was related to copanlisib, 2 CLL patients were related to duvelisib, and 2 CLL were related to idealisib...With regards to paraneoplastic treatment, topical treatment included corticosteroids, emollients, topical urea, retinoids, and fluorouracil. Systemic treatments included methotrexate, systemic corticosteroids, and phototherapy...Specialists should maintain a high index of suspicion for PRP as a paraneoplastic signal or drug-related adverse event. Future studies are needed to elucidate such presentations and guide management."

Chronic Lymphocytic Leukemia • Dermatology • Dermatopathology • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Lymphoma • Multiple Myeloma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology

Enhanced outcomes for pediatric patients with de novo chronic myeloid leukemia in blast Phase through early allogeneic stem cell transplantation and tyrosine kinase inhibitor (ASH 2025) - "Specifically, dasatinib was administered to four patients, while olverembatinib for three patients...Prophylaxis for graft-versus-host disease (GVHD) routinely included cyclosporine A and mycophenolate mofetil, with or without methotrexate... Prompt HSCT for de novo CML-BP, combined with early TKI maintenance post-transplantation, appears to contribute to effective disease management. Additionally, unrelated cord blood donors seem to provide a viable source for transplantation. Furthermore, olverembatinib has demonstrated favorable safety and efficacy profiles both pre- and post-transplantation."

Clinical • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Chronic Myeloid Leukemia • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Pediatrics • Transplantation • ABL1

Hetrombopag for enhancing platelet engraftment after haploidentical allogeneic hematopoietic stem cell transplantation in patients with severe thalassemia: An observational study (ASH 2025) - P | "Graft-versus-host disease prophylaxis included cyclophosphamide at a total dose of 100 mg/kg (divided into two doses on day +3 and +4), methotrexate at 10 mg/m² (administered on days +1, +2, +5, and +6), and cyclosporine A at 4 mg/kg/day starting from day +6. A significant difference in transfusion volume between groups may have introduced bias in post-transplant outcome analysis. These findings suggest that relying solely on platelet engraftment time as a measure of engraftment efficacy may be inadequate and potentially limiting."

Clinical • Observational data • Beta-Thalassemia • Bone Marrow Transplantation • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Immunology • Liver Failure • Musculoskeletal Pain • Nephrology • Transplantation

Outcomes of allogeneic hematopoietic stem cell transplantations (HSCT) for treatment of secondary primary malignancies arising post-autologous HSCT for multiple myeloma (ASH 2025) - "As conditioning regimens, 12 patients received Fludarabine/Busulfan, and 5 patients received Fludarabine/Melphalan...For GVHD prophylaxis, 6 patients received Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil (MMF); 9 patients received Thymoglobulin, Tacrolimus, and MMF; 1 patient received Thymoglobulin, Sirolimus, and MMF; 1 patient received Tacrolimus, Methotrexate, and Abatacept...Limitations of the outcome data include a relatively small population that underwent Allo-HCST, likely lower than the true number of patients with SPM following Auto-HSCT due to them either not returning to the center or opting against Allo-HSCT for treatment. This data adds to the collective understanding of the associated risks and benefits of Allo-HSCT for treatment of hematological SPM following Auto-HSCT for MM."

Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Multiple Myeloma • Myelodysplastic Syndrome • Oncology • Transplantation • TP53

Long-term HIV remission of a perinatally infected individual, following a hematopoietic cell transplantation from a CCR5Δ32 homozygous donor for multiple myeloma: The kyiv patient (ASH 2025) - "Complete remission (CR) was achieved after one cycle of melphalan/prednisone and local radiotherapy, but an abdominal relapse occurred six months later. Despite subsequent lines of therapy (bortezomib(bort)/lenalidomide(lena)/dexamethasone(dexa) and bendamustine/bort/dexa), the extramedullary multiple myeloma (MM) progressed. Remission was achieved after dexa/thalidomide/cisplatin/doxorubicin/cyclophosphamide/etoposide (DT-PACE) and an autologous HCT performed on 1/2021...Allogeneic HCT was performed in 8/2022 after fludarabine/melphalan conditioning and anti-thymocyte globulin from a CCR5-Δ32homozygous, unrelated HLA-matched donor; cyclosporine/methotrexate was utilized as graft-versus-host diseas e (GVHD) prophylaxis... To our knowledge, this represents the first report of ART-free HIV RNA suppression following allogeneic HCT with a CCR5Δ32homozygous donor in an individual perinatally infected with HIV. Despite the differences in the latent reservoir and the mechanism..."

Clinical • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Human Immunodeficiency Virus • Immunology • Infectious Disease • Multiple Myeloma • Plasmacytoma • Transplantation • CCR5 • CD4 • CD8

Long-term follow-up of novel post-transplant cyclophosphamide (PTCy) and abatacept (aba) graft-versus-host disease (GVHD) prophylaxis regimen compared to tacrolimus and methotrexate. (ASH 2025) - "This exploratory analysis found the intervention, PTCy + aba GVHD prophylaxis, at 2-5 year long-term follow-up was associated with sustained decreased cGHVD, with no difference in cGRFS and OS compared to the Control arm. There was a trend for more relapses on the PTCy + aba arm. This was confounded by small sample size and the fact that patients were stratified based on GVHD and not relapse risk, resulting in more patients with high-risk disease on the intervention arm.QoL at long-term follow-up was not different between arms, with results also limited by small sample size and confounded by non-response bias."

Post-transplantation • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Transplantation

Early detection of emerging safety signals in GVHD prophylaxis agents using a 12-year faers "slope-watch" approach (ASH 2025) - "In addition to tacrolimus and cyclosporine, contemporary prophylaxis regimens employ sirolimus and everolimus, mycophenolate mofetil, methotrexate, post-transplant cyclophosphamide (PTCy), JAK inhibitors (ruxolitinib, baricitinib, tofacitinib), co-stimulation blockade with abatacept, gut-homing integrin antagonism via vedolizumab, and the ROCK2 inhibitor belumosudil. Sequential IC-Δ offers a robust, forward-looking pharmacovigilance framework that identifies adverse event acceleration 12–24 months before regulatory action. By emphasizing directional change and incorporating a simple confidence approximation, this approach enhances early signal detection in large safety datasets. Integration with electronic health records, regulatory pipelines, and interactive dashboards could further streamline horizon scanning and improve patient safety in GVHD prophylaxis."

Clinical • Bone Marrow Transplantation • CNS Disorders • Cytomegalovirus Infection • Dyslipidemia • Graft versus Host Disease • Hemophagocytic lymphohistiocytosis • Hepatology • Immunology • Infectious Disease • Metabolic Disorders • Pneumonia • Rare Diseases • Respiratory Diseases • Septic Shock

Effect of GVHD prophylaxis on renal function and survival outcomes in allogeneic hematopoietic cell transplant patients with pre-existing renal impairment (ASH 2025) - "The advent of post-transplant cyclophosphamide (PTCy) permitted calcineurin inhibitor free graft-versus-host disease (GVHD) prophylaxis when combined with sirolimus (SIR), offering an HCT option that is less nephrotoxic...GVHD prevention regimens included PTCy/SIR, PTCy with tacrolimus (PTCy/TAC), TAC/SIR, and Tac with methotrexate (TAC/MTX)... Half of the patients with pre-existing RI, particularly those with eGFR <60, are at high risk of developing AKI post-HCT. While immunosuppression can significantly influence the risk of AKI, PTCy/SIR demonstrates a more favorable impact on renal function after HCT. These findings support the preferential use of PTCy/SIR as GVHD prophylaxis to reduce the risk of renal toxicity and associated morbidities, including need for dialysis post-HCT."

Clinical • Acute Kidney Injury • Cardiovascular • Diabetes • Diabetic Nephropathy • Graft versus Host Disease • Hematological Malignancies • Hypertension • Immunology • Metabolic Disorders • Nephrology • Renal Disease • Transplantation

Real-world experience with ruxolitinib therapy for steroid-refractory acute graft-versus-host disease following umbilical cord blood transplantation (ASH 2025) - "GVHD prophylaxis consisted of tacrolimus (Tac) plus mycophenolate mofetil in 54 patients and Tac plus short-term methotrexate in 1. RUX therapy for SR-aGVHD following UCBT showed a meaningful response rate, with sustained benefit observed in responders. Although cytopenias and infections were frequently encountered, most patients were able to continue treatment. RUX may represent a viable treatment option for SR-aGVHD in the UCBT setting, with careful attention to adverse events."

Clinical • Real-world • Real-world evidence • Acute Graft versus Host Disease • Bone Marrow Transplantation • Cerebral Hemorrhage • CNS Disorders • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Influenza • Neutropenia • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases • Septic Shock • Thrombocytopenia • Transplantation

Effectiveness of belumosudil in acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT): A real-world observational study (ASH 2025) - "All patients received myeloablative conditioning, with 75% of patients administered the fludarabine plus modified TBI regimen incorporating craniospinal, marrow, and nodal targets. Standard GVHD prophylaxis was cyclosporine/MMF/methotrexate + anti-CD25/ATG/ALG...Conclusion : This study provides the first disclosed real-world evidence of belumosudil in acute GVHD, demonstrating unprecedented 100% ORR (75% cases with a complete response) with rapid median time to response of 13.5 days and well tolerated. Despite the inherent limitations of this pilot investigation, these findings warrant validation in pivotal multicenter trials."

Clinical • Observational data • Real-world • Real-world evidence • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Dermatology • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Respiratory Diseases • Transplantation • CD80 • CD86 • IL17A • IL21 • STAT5

A novel reduced-toxicity conditioning regimen with busulfan/fludarabine/cyclophosphamide/anti-thymocyte globulin for severe aplastic anemia (ASH 2025) - "The conditioning regimen comprised Bu (0.8 mg/kg every 6 hours, 1 day, weight-adjusted dose for pediatric patients), Flu (30 mg/m²/day, 4 days), Cy (500 mg/m²/day, 4 days), and ATG with Thymoglobulin 2 mg/kg/day, 4 days in 3 patients or ATG-Fresenius 5 mg/kg/day, 4 days in 7 patients. Graft-versus-host disease (GVHD) prophylaxis included cyclosporine and mycophenolate mofetil for all patients, supplemented with either: short-term methotrexate(MTX, +1d 15mg/m², +4d, +8d, +11d 10mg/m², n=2); only CD25 monoclonal antibody(Basiliximab, +3d 20mg, n=1); or both(MTX as above plus Basiliximab, +3d 20mg, n=2; or MTX as above plus Recombinant humanized anti-CD25 monoclonal antibody, +4d, +8d, 1mg/kg, n=5)...Majority of the patients are with good quality of life. Longer follow-up and larger series are needed to evaluate fertility and transplant outcomes with current protocol."

Acute Graft versus Host Disease • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology

Efficacy of a second allogeneic hematopoietic cell transplant in myeloid heematologic malignancies (ASH 2025) - "Conditioning regimen: 3 patients encountering graft failure received reduced intensity conditioning, while 9 relapsing patients received total body irradiation (8Gy) and thiotepa (5mg/kg for 2 days) based myeloablative conditioning. GVHD prophylaxis included porcine anti human lymphocyte immunoglobulins, tacrolimus, methotrexate and/or anti-CD25 antibody...Univariate analyses suggested ECOG (>2) and HCT-CI(>1) score were correlated with patient survival after second allo-HCT. Conclusion The findings of our current study indicate that a second allo-HCT is a reasonable treatment choice for AML and MDS patients relapsing or encountering graft failure after a first allo-HCT, complete response and survival benefit may be anticipated particularly in those with better performance status and fewer comorbidities."

Clinical • Acute Myelogenous Leukemia • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Myelodysplastic Syndrome • Oncology • Pneumonia • Respiratory Diseases • Transplantation

Transplant outcomes for children and adolescents with severe aplastic anemia comparing matched sibling donor and haploidentical transplant approaches. (ASH 2025) - "Introduction Recent studies comparing matched sibling donor (MSD) and haploidentical donor with post-transplant cyclophosphamide (haplo-PTCy) hematopoietic stem cell transplantation (HSCT) for children and adolescents with severe aplastic anemia (SAA) show promising results...GVHD prophylaxis included cyclosporine A (3–5 mg/kg) and mini-methotrexate...The conditioning regimen included ATG 4.5 mg/kg, fludarabine 150 mg/m², and total body irradiation 400 cGy. GVHD prophylaxis consisted of Cy 50 mg/kg on +3 and +4, followed by tacrolimus 0.06 mg/kg and mycophenolate mofetil 30 mg/kg starting on +5...Discussion and Conclusions Health-related quality of life outcomes is comparable between the two approaches, with no significative differences in overall survival between both transplant models. These results suggest that haplo-HSCT with PT-Cy is a viable alternative when an MSD is unavailable and may open the possibility of further research studies in which this transplant..."

Clinical • Acute Graft versus Host Disease • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Respiratory Diseases • Transplantation

Clinical outcomes and prognostic factors in AML patients undergoing second allogeneic hematopoietic stem cell transplantation (ASH 2025) - "GVHD prophylaxis consisted of a calcineurin inhibitor and a short course of methotrexate. Anti-thymocyte globulin was administered in 95 patients (68.8%), while post-transplant cyclophosphamide was not used during the study period...However, disease status at SCT2 and the interval between SCT1 and relapse emerged as key prognostic factors. The overall suboptimal outcomes of allo-HCT2, driven by high rates of relapse and NRM, highlight the need for improved strategies, including optimized patient selection, enhanced GVHD prophylaxis, and post-transplant maintenance approaches."

Biomarker • Clinical • Clinical data • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Transplantation

This is a title in sentence case:early intrathecal dexamethasone and methotrexate as an effective approach for immune effector cell-associated neurotoxicity syndrome after CAR-T cell therapies (ASH 2025) - "Median duration of intravenous dexamethasone before first IDM was 6(1-7) (days). Our data shows that early administration of IDM is feasible and highly effective in management of severe or steroid-refractory ICANS and improving short-term prognosis, which may create opportunities for subsequent treatments in these patients. Larger sample and multicenter clinical trials are warranted to further validate these findings."

CAR T-Cell Therapy • Clinical • Acute Myelogenous Leukemia • B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • CD123 • CD22 • CD7 • IL3RA

Daclizumab enhances aGVHD prophylaxis by modulating T-cell polarization while preserving the graft-versus-lymphoma effect (ASH 2025) - "Our prior clinical data showed that adding Daclizumab, an anti-CD25 monoclonal antibody, to standard prophylaxis (Mycophenolate mofetil/Tacrolimus/Methotrexate) significantly reduced grade 3–4 aGvHD incidence in thalassemia patients undergoing alternative donor HSCT. Daclizumab enhances aGvHD prophylaxis by modulating T-cell polarization—favoring Th2/Treg balance and reducing cytotoxicity—while preserving graft-versus-lymphoma effects. These findings support anti-CD25 antibodies as a promising strategy to optimize immune tolerance and anti-tumor efficacy post-transplantation."

Acute Graft versus Host Disease • Bone Marrow Transplantation • Genetic Disorders • Graft versus Host Disease • Hematological Malignancies • Immunology • Lymphoma • CD4 • CD69 • CD8 • GZMB • IFNG • IL17A • IL2 • IL4 • PRF1

Favorable Outcomes of Bridging Glofitamab Prior to anti-CD19 CAR-T cell Therapy in patients with non-Hodgkin lymphoma (ASH 2025) - " Pts with R/R NHL who underwent leukapheresis received pre-treatment with obinutuzumab prior to the first dose of glofitamab. Based on disease progression status, pts received glofitamab monotherapy or glofitamab combined with gemcitabine + oxaliplatin/ BTK inhibitor/ methotrexate regimens prior to CAR-T infusion... Glofitamab bridging therapy prior to CAR-T demonstrated promising efficacy in pts with high-risk NHL, without significant safety concerns or detrimental impact on CAR-T cell kinetics. This study provides preliminary evidence for redefining therapeutic paradigms in non-Hodgkin lymphoma, particularly PCNSL, supporting further investigation through expanded validation cohorts and longitudinal outcomes assessment."

CAR T-Cell Therapy • Clinical • IO biomarker • B Cell Lymphoma • Bone Marrow Transplantation • Burkitt Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • TP53

Reduced-dose whole brain radiotherapy is an effective consolidation strategy for parenchymal-only secondary cns lymphoma (ASH 2025) - "Seven received methotrexate (MTX)-based induction regimens...Additional consolidative systemic therapy was delivered after RT in five patients, which included cytarabine (n=4) and rituximab (n=1)...Two patients experienced extracranial relapse; one of these received salvage therapy with polatuzumab vedotin/bendamustine/rituximab... This cohort suggests that consolidative reduced-dose WBRT may be a valuable consolidation option for certain transplant-ineligible chemo-responsive SCNSL patients, with encouraging and sometimes durable responses. The absence of leptomeningeal and systemic disease at the time of RT may help guide patient selection. These findings support further prospective evaluation and raise the possibility of a new, previous-underexplored role for RT in the management of SCNSL."

B Cell Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Secondary Central Nervous System Lymphoma

Early-onset T-cell large granular lymphocytic leukemia in a 24-year-old woman: A rare case with confirmed clonality and immune-mediated cytopenias (ASH 2025) - "The patient was treated with oral methotrexate 10 mg once weekly, folic acid 1 mg daily, and prednisone 20 mg daily. This case highlights the importance of considering clonal T-cell proliferative disorders in the differential diagnosis of unexplained cytopenias—even in young adults. It expands the clinical spectrum of early-onset T-LGLL and underscores the need for increased recognition, timely diagnosis, and further research into its pathogenesis and optimal therapeutic strategies."

Clinical • IO biomarker • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Rheumatology • T-Cell Large Granular Lymphocyte Leukemia • B3GAT1 • CALR • CD8 • JAK2 • STAT3

From unexplained cytopenias to clonality: Diagnosing T-cell large granular lymphocytic leukemia in rheumatoid arthritis via integrated molecular profiling (ASH 2025) - "We present a diagnostically complex case of T-LGL leukemia in the setting of longstanding RA, initially misattributed to hydroxychloroquine-induced cytopenia...The patient was started on prednisone 60 mg daily for 7 days, leading to a prompt rise in ANC to 1.4 × 10⁹/L, followed by tapering...Plans were made to initiate low-dose methotrexate for treatment of both T-LGL and RA...In this case, the clinical suspicion for clonal lymphoproliferative disease remained high despite inconclusive flow cytometry, prompting further molecular testing that ultimately confirmed the diagnosis. An integrated diagnostic approach that includes molecular and clonality testing can help distinguish T-LGL leukemia from reactive or drug-induced cytopenias, enabling timely and targeted immunosuppressive therapy."

Hematological Disorders • Hematological Malignancies • Immunology • Inflammatory Arthritis • Leukemia • Leukopenia • Pulmonary Disease • Rheumatoid Arthritis • Rheumatology • T-Cell Large Granular Lymphocyte Leukemia • CD8 • STAT3 • TNFAIP3 • TRG

Anti-CD94 monoclonal antibody DR-01 induced response in a refractory primary CNS T-cell lymphoma (ASH 2025) - "The patient received methotrexate-based chemotherapy with a complete response and associated improved deficits followed by high dose chemotherapy with autologous stem cell rescue consolidation in 12/2023...Treatment is ongoing without significant adverse events or recurrence 15 months after treatment initiation. Our patient demonstrates for the first time, clinical activity of DR-01 in a patient with CNS involvement."

CNS Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral T-cell Lymphoma • Primary Central Nervous System Lymphoma • T Cell Non-Hodgkin Lymphoma • CD8 • GZMB • KLRD1

Combinatorial targeting of metabolic vulnerabilities in t-cell leukemia through NAMPT inhibition (ASH 2025) - "Despite advances in multi-agent chemotherapy, including the use of antimetabolites like methotrexate (MTX) , a substantial proportion of patients relapse or develop drug resistance, with limited effective therapeutic alternatives...By linking NAD⁺ metabolism to folates pathway regulation, our study uncovers a novel mechanism for overcoming drug resistance that is particularly relevant for high-risk or relapsed T-ALL cases. This work provides a strong preclinical rationale for investigation of NAMPT inhibition in combination with MTX , especially in patients who have developed resistance to standard therapies, with the potential of expanding these findings to other solid and hematological cancers where MTX is established as part of the treatment."

Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Metabolic Disorders • T Acute Lymphoblastic Leukemia • T-cell Acute Lymphoblastic Lymphoma • DHFR • NAMPT